Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Flumatinib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Flumatinib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Flumatinib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Flumatinib
Generic Name (API): Flumatinib Mesylate
Dosage Form & Strength: 100 mg, 200 mg
Route: Oral
Drug Class: BCR-ABL1 tyrosine kinase inhibitor

Manufacturer / Innovator:

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Flumatinib Used For?

Flumatinib is a once-daily tablet for adults with chronic myeloid leukaemia (CML) that carries the Philadelphia chromosome and is still in the chronic phase. It was discovered and is made in China by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharmaceutical Group, and is sold there as 豪森昕福 (Hansoh Xinfu®). During development it was known as HH-GV678.

China's National Medical Products Administration (NMPA) approved it on 22 November 2019. The Chinese label gives a single use:

  • Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML), chronic phase, in adults

The label does not limit this to a particular line of treatment, but the main trial behind the approval enrolled people who had been diagnosed within the previous six months and had not yet taken any tablet of this type. Whether it suits a particular patient is a decision for a haematologist with experience in CML. Our haematology medicines section lists other blood cancer treatments we can help import.

How It Works

In CML, two chromosomes swap pieces and form the Philadelphia chromosome. This creates a fused gene, BCR-ABL1, which makes an enzyme that is permanently switched on and tells the bone marrow to keep producing white blood cells. This medicine is a tyrosine kinase inhibitor: it blocks the BCR-ABL1 enzyme so the leukaemia cells stop receiving that growth signal. In laboratory tests it switched off the enzyme at very low concentrations, and one of its breakdown products in the body is active as well.

What the Trial Showed

Approval rested on FESTnd (study HS-10096-301, NCT02204644), a phase 3 trial at Chinese centres. It randomised 394 adults with newly diagnosed chronic-phase CML to this tablet at 600 mg once a day or to a comparison medicine, an older standard tablet, for 12 months.

  • Major molecular response at 6 months (the main goal of the study): 33.7% versus 18.3%
  • Major molecular response at 12 months: 52.6% versus 39.6%
  • Early response at 3 months: 82.1% versus 53.3%
  • Deeper (MR4) response at 12 months: 23.0% versus 11.7%
  • No patient taking it moved on to the accelerated or blast phase within 12 months, compared with 4 patients in the comparison group.

The label also reports that a major molecular response came sooner, at a median of 8.5 months against 11.3 months.

Recommended Dosage

  • Usual dose: 600 mg by mouth once a day, for example three 200 mg tablets taken together
  • Empty stomach: nothing to eat for 2 hours before and 1 hour after each dose. A high-fat meal more than doubled the peak blood level in studies, which is why timing matters.
  • How to take it: keep to a fixed time of day and take the tablets whole with a glassful of water; breaking or chewing them is not advised
  • Dose steps: if blood counts drop too low or other side effects become hard to manage, treatment is paused and may restart at 400 mg and then 300 mg; if problems return at 300 mg, it is stopped
  • How long: it continues for as long as the patient benefits, or until the disease progresses or side effects cannot be tolerated

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Who should not take it: anyone allergic to the active substance or any ingredient in the tablet. In the main trial, 41.8% of patients had at least one side effect of grade 3 or higher, so regular check-ups are part of treatment.

  • Low blood counts: the most common problem. Platelets fell in 52.6% of patients (24.5% severe) and neutrophils in 31.6% (17.9% severe). The label advises a full blood count every week in the first month, every two weeks in the second month and monthly after that. Report fever, unusual bruising or bleeding straight away.
  • Diarrhoea and stomach upset: diarrhoea affected 38.8%, tummy pain 15.8% and vomiting 14.3%, almost always mild to moderate.
  • Liver: ALT rose in 27.6% and AST in 17.3%. Liver tests are checked before starting and then about once a month. People with liver problems need extra care.
  • Pancreas enzymes: lipase rose in 12.8% (5.6% severe) and amylase in 8.2%. Severe tummy pain should be checked to rule out pancreatitis, and people who have had pancreatitis should use it with caution.
  • Heart rhythm: 10.7% had heart effects, all mild or moderate and mostly a slow heartbeat (4.1%). No QT prolongation was seen in the trials, but because related medicines can cause it, ECGs and potassium and magnesium levels are watched. Older people and anyone with heart disease should have heart function checked before starting.
  • Bleeding: serious bleeding, including heavy periods and bleeding in the brain, has been reported. Extra care is needed with blood thinners or medicines that affect platelets.
  • Low phosphate and fluid retention: phosphate fell in 13.8%. Mild puffiness around the face or eyes occurred in 4.1%; sudden weight gain should be reported.

Other points: it is broken down mainly by the liver enzyme CYP3A4, so strong blockers or boosters of that enzyme (found among some antibiotics, antifungals, HIV medicines and epilepsy medicines) should be avoided or used only under medical advice. There is no information on use in pregnancy or breastfeeding; women who could become pregnant should use effective contraception, and it is given in pregnancy only if the benefit clearly outweighs the risk to the baby. Safety in people under 18 has not been established, and dizziness or tiredness may affect driving. Caution is also advised in people with glaucoma, heart failure risk or past kidney failure.

How to Access Flumatinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Flumatinib to India?

The tablets are imported for one named patient, by the patient or a hospital, under India's rules for importing unapproved medicines. Please keep these ready:

  • A prescription from a haematologist or haemato-oncologist stating the dose
  • A report confirming Ph+ CML, such as a BCR-ABL1 PCR test or a bone marrow chromosome study, and a note that the disease is in the chronic phase
  • Recent blood counts and liver tests, plus details of any earlier CML treatment
  • Government-issued photo ID of the patient

How is the order confirmed?

Once we have checked a valid prescription and, where required, the import permit has been issued.

Is Flumatinib available in India?

No. CDSCO has not approved it, so Indian pharmacies do not stock it. It is approved only in China; the US FDA and the European Medicines Agency have not approved it.

A patient can still receive it through the Named Patient Program (NPP), which allows a medicine without Indian registration to be imported for one person on a doctor's prescription. We also help families access other China-approved leukaemia tablets, such as lisaftoclax for chronic lymphocytic leukaemia.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for the tablets to be kept sealed below 30°C, so the boxes travel unopened under temperature-controlled shipping that avoids heat exposure on the way. At the standard dose a patient needs three 200 mg tablets a day, roughly three 30-tablet boxes a month, and we plan shipments so a new supply arrives before the current one runs out. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Because CML treatment runs for years, most families want a dependable monthly supply. Once the haematologist's prescription and import papers are in order, the tablets can be sent to the cities below and many smaller towns.

Delhi

Haematology clinics in Delhi see many newly diagnosed CML patients, and dispatch from New Delhi means the tablets usually reach them quickly.

Mumbai

A haematologist in Mumbai can send the BCR-ABL1 report and prescription, and we deliver to the patient's home or hospital pharmacy.

Bangalore

Families in Bangalore get a written quote for a month's supply first, so they can plan before anything is ordered.

Chennai

For patients in Chennai, we line up each delivery with the blood-count reviews that are frequent in the first two months.

Hyderabad

Leukaemia teams in Hyderabad can request the tablets for a named patient once the chronic phase is confirmed.

Kolkata

CML patients in Kolkata and the north-eastern states can have each monthly box couriered from Delhi, with the dispatch details shared by message.

Pune

We help families in Pune keep a steady monthly supply, since this daily tablet works best when doses are not missed.

Ahmedabad

Doctors in Ahmedabad can share the diagnosis and treatment history, and we explain which papers are still pending.

Vellore

Patients followed up at hospitals in Vellore can have the boxes sent to the hospital to match their clinic visits.

Chandigarh

Haematologists in Chandigarh treating patients from Punjab, Haryana and Himachal can ask us to send the tablets ahead of each review visit.

Lucknow

In Lucknow, a family can choose delivery at home or to the leukaemia clinic where the PCR tests are done.

Kochi

For Kerala, monthly parcels go to Kochi, Thrissur or another town close to the patient.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 19 November 2026

More Hematology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP